Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug [Yahoo! Finance]
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer [Yahoo! Finance]
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
Nuvectis Pharma GAAP EPS of -$0.24 beats by $0.01 [Seeking Alpha]
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights